Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.69 |
| ▸ | CLPP | Q16740 | 1/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971396 | 1.00 | GRM5 (0.69) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL1971215 | 0.92 | GRM5 (0.73) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL1971211 | 0.92 | GRM5 (0.73) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL1968647 | 0.89 | GRM5 (0.55) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL1968643 | 0.89 | GRM5 (0.55) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL1972342 | 0.89 | GRM5 (0.69) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL1969865 | 0.89 | GRM5 (0.69) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL1969863 | 0.89 | GRM5 (0.69) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL1972345 | 0.89 | GRM5 (0.69) | GRM5CLPPATML3MBTL1MEN1 | |
| SCHEMBL1973388 | 0.87 | GRM5 (0.67) | GRM5CLPPATML3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912979-B1 | PHENYL-{3-(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2011-06-22 | — | — | EP | claimed |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | claimed |
| EP-1912979-A2 | PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2008-04-23 | — | — | EP | claimed |
| WO-2006123257-A2 | PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | claimed |
| EP-1912979-B1 | PHENYL-{3-(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | disclosed |
| EP-1912979-A2 | PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2006123257-A2 | PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | GRM5, GRIK5, GRM2 | GRM5 1/4885CLPP 4541/4885ATM 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.